WO1995026325B1 - Enhancement of the efficacy of drugs by deuteration - Google Patents
Enhancement of the efficacy of drugs by deuterationInfo
- Publication number
- WO1995026325B1 WO1995026325B1 PCT/CA1995/000154 CA9500154W WO9526325B1 WO 1995026325 B1 WO1995026325 B1 WO 1995026325B1 CA 9500154 W CA9500154 W CA 9500154W WO 9526325 B1 WO9526325 B1 WO 9526325B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nifedipine
- solution
- dihydropyridine
- deuterated
- compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 4
- 229940079593 drugs Drugs 0.000 title abstract 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract 16
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract 9
- 229960001597 Nifedipine Drugs 0.000 claims abstract 7
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims abstract 7
- 238000001346 gas chromatography-isotope ratio mass spectrometry Methods 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 13
- YNGDWRXWKFWCJY-UHFFFAOYSA-N dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 7
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims 6
- 229910052805 deuterium Inorganic materials 0.000 claims 6
- 125000004431 deuterium atoms Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 6
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims 3
- 238000007710 freezing Methods 0.000 claims 3
- 238000010438 heat treatment Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000007789 sealing Methods 0.000 claims 3
- 230000000155 isotopic Effects 0.000 claims 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 229960003580 Felodipine Drugs 0.000 claims 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229960001783 Nicardipine Drugs 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 229950000109 Niludipine Drugs 0.000 claims 1
- VZWXXKDFACOXNT-UHFFFAOYSA-N Niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 claims 1
- 229960000715 Nimodipine Drugs 0.000 claims 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N Nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 claims 1
- 229960000227 Nisoldipine Drugs 0.000 claims 1
- 229960005425 Nitrendipine Drugs 0.000 claims 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N Nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- 230000003276 anti-hypertensive Effects 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 1
- 239000002547 new drug Substances 0.000 abstract 2
- 230000002708 enhancing Effects 0.000 abstract 1
- 230000001077 hypotensive Effects 0.000 abstract 1
Abstract
A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines) and particularly of nifedipine wherein one or more hydrogen atoms are deuterated and wherein the deuterated nifedipine has unexpectedly improved hypotensive properties when used in much lower concentrations than nifedipine per se. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by gas chromatography-isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
Claims
1. A compound wherein at least one of the hydrogen atoms is replaced with a deuterium atom, wherein said compound is a dihydropyridine.
2. The compound according to claim 1, wherein said dihydropyridine is deuterated nifedipine having the formula
wherein at least one of the hydrogen atoms is a deuterium atom.
3. The compound according to claim 2, wherein at least one of the methyl groups of said deuterated nifedipine is CD3.
4. The compound according to claim 1, wherein methyl groups are attached to positions 2 and 6 of the dihydropyridine ring, and at least one of them is substituted with CD3.
5. The compound according to claim 4, wherein said deuterated dihydropyridine is deuterated nifedipine having the formula
6. The compound according to claim 1, wherein said dihydropyridine is nifedipine, nicardipine, nimodipine, niludipine, nisoldipine, nitrendipine, felodipine, ifradipine or amlodipine.
36
7. A method for making a deuterated dihydropyridine wherein at least one of the H atoms is replaced with a deuterium atom, said method comprising: dissolving a dihydropyridine in a mixture of deuterochloroform and deuterium oxide to form a solution, adding trifluoroacetic anhydride and deuteroacetone to said solution, freezing and sealing said solution within a vessel, heating said solution at a temperature and for a period of time sufficient to deuterate all of the hydrogen atoms at the 2 and 6 position on said dihydropyridine, and recovering said deuterized dihydropyridine.
8. The method according to claim 7, wherein said deuterized dihydropyridine is deuterated nifedipine and said method comprises: dissolving nifedipine in a mixture of deuterochloroform and deuterium oxide to form a solution, adding trifluoroacetic anhydride and deuteroacetone to said solution, freezing and sealing said solution within a vessel, heating said solution at a temperature and for a period of time sufficient to deuterate all of the hydrogen atoms on the methyl groups at the 2 and 6 position on said nifedipine, and recovering said deuterized nifedipine.
9. The method according to claim 8, said method comprising: dissolving 80 mg of nifedipine in a mixture of about 2 ml of deuterochloroform and about 0.5 ml of deuterium oxide to form a solution, adding about 0.2 ml of trifluoroacetic anhydride and 2 ml of deuteroacetone to said solution and mixing therewith, freezing and sealing said solution within a vessel, heating said solution at a temperature of about 50° to about 65 °C for a period of time of about 150 to 180 hours, cooling said heated solution and recovering said deuterated nifedipine.
10. The method as defined in claim 9 wherein said temperature is about 55° to about 60°C.
11. The method as defined in claim 9 wherein said period of time is from about 160 to 170 hours.
37
12. The method as defined in claim 9 wherein said temperature is about 57 °C and said period of time is about 168 hours.
13. A method for the treatment of hypertension in an animal suffering therefrom comprising administering to said animal a therapeutically effective amount of a deuterated nifedipine wherein at least one of the H atoms is replaced with a deuterium atom.
14. A method as in claim 13 wherein methyl groups are attached to positions 2 and 6 of the dihydropyridine ring, and at least one of them is substituted with CD3.
15. A method of detecting whether a pharmaceutical compound is identical and/or bioequivalent to a known pharmaceutical compound comprising the steps of
(a) determining the molecular and isotopic structure of said known pharmaceutical compound by gas chromatography-isotope ratio mass spectrometry,
(b) determining the molecular and isotopic structure of said pharmaceutical compound subject to said detection by gas chromatography-isotope ratio mass spectrometry,
(c) comparing the results of said two determinations to detect any isotope variation in the molecular structure of said pharmaceutical compound over that of the known pharmaceutical compound.
16. The use of a deuterated nifedipine wherein at least one of the H atoms is replaced with a deuterium atom, as an antihypertensive drug.
17. A use as in claim 16 wherein methyl groups are attached to positions 2 and 6 of the dihydropyridine ring, and at least one of them is substituted with CD3.
18. The use of a deuterated nifedipine wherein at least one of the H atoms is replaced with a deuterium atom, for preparing an antihypertensive medicament.
19. The use as in claim 18 wherein methyl groups are attached to positions 2 and 6 of the dihydropyridine ring, and at least one of them is substituted with CD3.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9507200A BR9507200A (en) | 1994-03-25 | 1995-03-27 | Improved drug efficacy by deuteration |
DE69535592T DE69535592T2 (en) | 1994-03-25 | 1995-03-27 | IMPROVING THE EFFECTIVENESS OF MEDICINES BY DEUTERIZATION |
KR1019960705390A KR100477070B1 (en) | 1994-03-25 | 1995-03-27 | Enhancing the efficacy of pharmaceuticals by deuteration |
EP95912109A EP0751926B1 (en) | 1994-03-25 | 1995-03-27 | Enhancement of the efficacy of drugs by deuteration |
AU19441/95A AU707748B2 (en) | 1994-03-25 | 1995-03-27 | Enhancement of the efficacy of drugs by deuteration |
KR10-2004-7010591A KR20040068613A (en) | 1994-03-25 | 1995-03-27 | Deuterated compound and composition for treating hypertension |
JP52488595A JP3696884B2 (en) | 1994-03-25 | 1995-03-27 | Enhancement of drug efficacy by deuteration |
MXPA/A/1996/004309A MXPA96004309A (en) | 1994-03-25 | 1996-09-25 | Increased drug effectiveness by deuterac |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21789794A | 1994-03-25 | 1994-03-25 | |
US08/217,897 | 1994-03-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1995026325A2 WO1995026325A2 (en) | 1995-10-05 |
WO1995026325A3 WO1995026325A3 (en) | 1995-12-14 |
WO1995026325B1 true WO1995026325B1 (en) | 1996-02-01 |
Family
ID=22812932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1995/000154 WO1995026325A2 (en) | 1994-03-25 | 1995-03-27 | Enhancement of the efficacy of drugs by deuteration |
Country Status (12)
Country | Link |
---|---|
US (1) | US5846514A (en) |
EP (1) | EP0751926B1 (en) |
JP (1) | JP3696884B2 (en) |
KR (2) | KR20040068613A (en) |
CN (1) | CN1087725C (en) |
AT (1) | ATE372966T1 (en) |
AU (1) | AU707748B2 (en) |
BR (1) | BR9507200A (en) |
CA (1) | CA2186371A1 (en) |
DE (1) | DE69535592T2 (en) |
ES (1) | ES2293638T3 (en) |
WO (1) | WO1995026325A2 (en) |
Families Citing this family (464)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US6355416B1 (en) * | 1997-02-14 | 2002-03-12 | The George Washington University | Assay for the measurement of DNA synthesis rates |
US6312450B1 (en) | 1997-05-20 | 2001-11-06 | Natural Vision Center, Inc. | System and method for improving the appearance of skin |
US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
EP1645565B1 (en) * | 1997-10-08 | 2009-02-18 | Isotechnika Inc. | Deuterated cyclosporine analogs and their use as immunomodulating agents |
ATE423130T1 (en) | 1997-10-08 | 2009-03-15 | Isotechnika Inc | DEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
US6333342B1 (en) * | 1998-11-04 | 2001-12-25 | Isotechnika, Inc | Methods of pharmacological treatment using S(−) amlodipine |
US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
US7323341B1 (en) * | 1999-07-09 | 2008-01-29 | Jasper John P | Stable isotopic identification and method for identifying products by isotopic concentration |
US6254594B1 (en) | 1999-07-30 | 2001-07-03 | Quadrivium, Llc | Disposable light source for photothermal treatment of human tissue |
RU2181297C2 (en) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Method of treatment of pathological syndrome and medicinal agent |
US6579630B2 (en) | 2000-12-07 | 2003-06-17 | Canon Kabushiki Kaisha | Deuterated semiconducting organic compounds used for opto-electronic devices |
US6872408B2 (en) * | 2001-09-07 | 2005-03-29 | Rupert C. Bell | Method of treating bipolar disorders using deuterium-substituted carbonate |
DE60233884D1 (en) * | 2001-10-16 | 2009-11-12 | Memory Pharmaceutical Corp | 4 (4-ALKOXY-3-HYDROXYPHENYL) -2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES |
ES2326040T3 (en) | 2001-10-19 | 2009-09-29 | Isotechnika Inc. | SYNTHESIS OF CYCLOSPORINE ANALOGS. |
RU2201255C1 (en) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Medicinal agent and method of regulation of vascular tonus |
DE10205432A1 (en) * | 2002-02-07 | 2003-08-21 | Bdd Group Holding Ag Zug | Deuterated biphenyl-substituted spirocyclopentanimidazolines and medicinal products containing these compounds |
UA76640C2 (en) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Method for correcting pathological immune responses and homeopathic medicinal agent |
UA76639C2 (en) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Homeopathic medication and method for treating erectile dysfunctions |
JP2006501246A (en) | 2002-08-30 | 2006-01-12 | メモリー・ファーマシューティカルズ・コーポレイション | Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
KR101129933B1 (en) | 2002-09-25 | 2012-03-23 | 메모리 파마슈티칼스 코포레이션 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
AU2003295656B2 (en) | 2002-11-19 | 2010-11-11 | Memory Pharmaceuticals Corporation | Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors |
WO2004082629A2 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
WO2004094375A2 (en) * | 2003-04-16 | 2004-11-04 | Memory Pharmaceuticals Corporation | 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors |
RU2379292C2 (en) * | 2003-04-18 | 2010-01-20 | Мемори Фармасьютиклз Корпорейшн | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
WO2005020840A2 (en) * | 2003-08-21 | 2005-03-10 | Thomas Tobin | Composition and method for marking procaine penicillin |
RU2253478C1 (en) * | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Agent for potentiation therapeutical effects: enhancing effect of drug |
EP1684806B1 (en) * | 2003-11-21 | 2008-06-25 | Memory Pharmaceuticals Corporation | Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors |
JP4995075B2 (en) | 2004-03-25 | 2012-08-08 | メモリー・ファーマシューティカルズ・コーポレイション | Indazole, benzothiazole, benzisothiazole, benzisoxazole, and their preparation and use |
US7705036B2 (en) * | 2004-04-01 | 2010-04-27 | Cardiome Pharma Corp. | Deuterated aminocyclohexyl ether compounds and processes for preparing same |
CA2561733A1 (en) * | 2004-04-01 | 2005-10-13 | Cardiome Pharma Corp. | Pegylated ion channel modulating compounds |
EP1809656A4 (en) * | 2004-09-29 | 2009-03-25 | Amr Technology Inc | Cyclosporin alkyne analogues and their pharmaceutical uses |
US7511013B2 (en) * | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
EP1799673A1 (en) | 2004-10-15 | 2007-06-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
JP2008517066A (en) * | 2004-10-20 | 2008-05-22 | メモリー ファーマシューティカルス コーポレーション | Phosphodiesterase 4 inhibitor |
MX2007005988A (en) | 2004-11-18 | 2007-07-10 | Cardiome Pharma Corp | Synthetic process for aminocyclohexyl ether compounds. |
BRPI0612138B8 (en) | 2005-06-15 | 2021-05-25 | Cardiome Pharma Corp | aminocyclohexyl ether compounds and method of making them |
KR101358509B1 (en) * | 2005-07-26 | 2014-02-05 | 다케다 게엠베하 | Isotopically substituted proton pump inhibitors |
JP5289951B2 (en) * | 2005-07-26 | 2013-09-11 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Isotopically substituted pantoprazole |
KR101380190B1 (en) | 2005-07-29 | 2014-04-11 | 콘서트 파마슈티컬즈, 인크. | Novel benzo [d][1,3]-dioxol derivatives |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
DK1954669T3 (en) | 2005-12-01 | 2015-10-12 | Auspex Pharmaceuticals Inc | SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY |
RU2309732C1 (en) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation |
US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
WO2007140189A2 (en) * | 2006-05-26 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted carboxylic acid compounds |
US8367414B2 (en) | 2006-05-30 | 2013-02-05 | Jasper John P | Tracing processes between precursors and products by utilizing isotopic relationships |
AU2007256893A1 (en) | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted imidazopyridine compounds with hypnotic effects |
EP2023721A2 (en) * | 2006-06-05 | 2009-02-18 | Auspex Pharmaceuticals Inc. | Preparation and utility of substituted erythromycin analogs |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
US20080039473A1 (en) * | 2006-08-08 | 2008-02-14 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
BRPI0714484A2 (en) | 2006-08-16 | 2013-04-24 | Auspex Pharmaceuticals Inc | compound, method of treating a mammal suffering from a disease or condition, method of treating a member suffering from a disease, disorder, symptom or condition and pharmaceutical composition |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
EP2131656A4 (en) * | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | Phthalazine derivatives |
US7932235B2 (en) | 2006-11-17 | 2011-04-26 | Concert Pharmaceuticals, Inc. | Triazolyl tropane derivatives |
US20080146573A1 (en) * | 2006-12-04 | 2008-06-19 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted oxzolidinones |
US8343950B2 (en) | 2006-12-15 | 2013-01-01 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
US8080549B2 (en) | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
WO2008088727A2 (en) * | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
WO2008106125A2 (en) | 2007-02-26 | 2008-09-04 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists |
ES2395241T3 (en) | 2007-03-07 | 2013-02-11 | Concert Pharmaceuticals Inc. | Deuterated piperazine derivatives as antianginal compounds |
EP3103790B1 (en) | 2007-03-15 | 2018-05-09 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamine with serotoninergic and/or norepinephrinergic activity |
ES2559838T3 (en) | 2007-03-16 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Cholesterol ester transfer protein inhibitors |
US7863308B2 (en) | 2007-04-10 | 2011-01-04 | Auspex Pharmaceuticals, Inc. | Substituted thiophenes |
EP2527336A1 (en) | 2007-04-25 | 2012-11-28 | Concert Pharmaceuticals Inc. | Deuterated analogues of cilostazol |
US8349817B2 (en) | 2007-04-25 | 2013-01-08 | Concert Pharmaceuticals, Inc. | Analogues of cilostazol |
EP2139848A1 (en) | 2007-04-26 | 2010-01-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
FI3825306T3 (en) | 2007-05-01 | 2023-08-23 | Concert Pharmaceuticals Inc | Morphinan compounds |
CN101687868B (en) | 2007-05-01 | 2012-12-12 | 康塞特医药品公司 | Morphinan compounds |
WO2008141021A1 (en) | 2007-05-08 | 2008-11-20 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors |
US20080280970A1 (en) | 2007-05-08 | 2008-11-13 | Czarnik Anthony W | Deuterium-enriched atorvastatin |
HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
US7531685B2 (en) * | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
DE602008000255D1 (en) | 2007-06-12 | 2009-12-17 | Concert Pharmaceuticals Inc | Azapeptide derivatives as HIV protease inhibitors |
US20080312318A1 (en) * | 2007-06-14 | 2008-12-18 | Protia, Llc | Deuterium-enriched escitalopram |
US20080318964A1 (en) * | 2007-06-19 | 2008-12-25 | Protia, Llc | Deuterium-enriched eszopiclone |
US7915309B2 (en) | 2007-06-20 | 2011-03-29 | Protia, Llc | Deuterium-enriched oseltamivir |
EP2170828B1 (en) | 2007-06-20 | 2012-11-21 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
WO2009009531A2 (en) | 2007-07-09 | 2009-01-15 | Concert Pharmaceuticals Inc. | Pyrimidinecarboxamide derivatives for the treatment of hiv infections |
EP2170825A2 (en) * | 2007-07-30 | 2010-04-07 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
ES2425183T3 (en) | 2007-08-14 | 2013-10-11 | Concert Pharmaceuticals Inc. | Substituted oxazolidinone derivatives |
US20090062182A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched dalbavancin |
US7767860B2 (en) | 2007-09-06 | 2010-08-03 | Auspex Pharmaceuticals, Inc | Substituted amino alcohols |
US20090069395A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched famotidine |
US8669268B2 (en) | 2007-09-12 | 2014-03-11 | Deuterx, Llc | Deuterium-enriched prasugrel |
US8304435B2 (en) | 2007-09-12 | 2012-11-06 | Deuteria Pharmaceuticals Inc. | Deuterium-enriched donepezil |
US8288414B2 (en) | 2007-09-12 | 2012-10-16 | Deuteria Pharmaceuticals, Inc. | Deuterium-enriched lenalidomide |
EP2197847B1 (en) | 2007-09-12 | 2012-11-07 | Concert Pharmaceuticals Inc. | Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection |
US7919516B2 (en) | 2007-09-13 | 2011-04-05 | Protia, Llc | Deuterium-enriched ondansetron |
US20090076161A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched bupropion |
CA2698808A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
US8026249B2 (en) | 2007-09-14 | 2011-09-27 | Deutena Pharmaceuticals, Inc. | Deuterium-enriched topotecan |
US7776866B2 (en) | 2007-09-15 | 2010-08-17 | Protia, Llc | Deuterium-enriched risperidone |
US7842675B2 (en) | 2007-09-15 | 2010-11-30 | Protia, Llc | Deuterium-enriched capecitabine |
US7956080B2 (en) | 2007-09-25 | 2011-06-07 | Protra, LLC | Deuterium-enriched SDX-101 |
US20090082259A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched octreotide |
US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
EP2212298B1 (en) * | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) * | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
US8592487B2 (en) | 2007-10-26 | 2013-11-26 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
JP2011503231A (en) * | 2007-11-20 | 2011-01-27 | コンサート ファーマシューティカルズ インコーポレイテッド | Peptides for treatment of HCV infection |
US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
ES2396366T3 (en) | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Heterocyclic Kinase Inhibitors |
US8084464B2 (en) | 2007-12-18 | 2011-12-27 | Concert Pharmaceuticals, Inc. | Tetrahydroisoquinoline derivatives |
EP2242493B1 (en) | 2008-01-22 | 2013-06-05 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
WO2009094210A1 (en) | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Vandetanib derivatives |
US20090221612A1 (en) | 2008-02-13 | 2009-09-03 | Mitchell Scott A | Certain substituted amides, method of making, and method of use thereof |
US20110059980A1 (en) * | 2008-02-21 | 2011-03-10 | Yasuaki Oobayashi | Solid preparation for oral administration |
EP2265334A2 (en) | 2008-02-29 | 2010-12-29 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
EP2268604B1 (en) * | 2008-03-14 | 2017-02-15 | Retrotope, Inc. | Therapies for cancer using isotopically substituted lysine |
RU2010142937A (en) * | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | NEW PIPERIDINE DERIVATIVES AS STEAROIL-COA DESATURASE INHIBITORS |
RU2010142936A (en) * | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | NEW PIPERASIN DERIVATIVES AS STEAROIL-COA DESATURASE INHIBITORS |
WO2009128947A1 (en) | 2008-04-17 | 2009-10-22 | Concert Pharmaceuticals, Inc. | Piperazine derivatives |
WO2009148600A2 (en) * | 2008-06-06 | 2009-12-10 | Concert Pharmaceuticals, Inc. | Deuterated lysine-based compounds |
US8354557B2 (en) | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
WO2009158005A1 (en) * | 2008-06-27 | 2009-12-30 | Concert Pharmaceuticals, Inc. | Benzazepinone compounds |
WO2010005520A2 (en) * | 2008-06-30 | 2010-01-14 | Concert Pharmaceuticals, Inc. | 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives |
WO2010002451A1 (en) * | 2008-07-01 | 2010-01-07 | Concert Pharmaceuticals, Inc. | Naphthyridin derivatives |
US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
TWI523652B (en) * | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | Deuterated benzylbenzene derivatives and methods of use |
US9056845B2 (en) | 2008-07-16 | 2015-06-16 | Richter Gedeon Nyrt. | Pharmaceutical formulations containing dopamine receptor ligands |
WO2010011868A2 (en) * | 2008-07-23 | 2010-01-28 | Auspex Pharmaceuticals | Pyridine sulfonamide modulators of endothelin-a-receptor |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
KR101671537B1 (en) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | Multi-arm polymeric alkanoate Conjugates |
WO2010019560A1 (en) * | 2008-08-12 | 2010-02-18 | Concert Pharmaceuticals Inc. | Deuterated derivatives of donepezil |
WO2010019557A1 (en) * | 2008-08-12 | 2010-02-18 | Concert Pharmaceuticals Inc. | N-phenyl-2-pyrimidineamine derivatives |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100074973A1 (en) * | 2008-08-27 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Thioxanthene modulators of dopamine d2 receptors |
PL2328414T3 (en) | 2008-08-29 | 2014-05-30 | Concert Pharmaceuticals Inc | Substituted triazolo-pyridazine derivatives |
NZ591315A (en) * | 2008-09-03 | 2012-08-31 | Teva Pharma | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
US8704001B2 (en) | 2008-09-16 | 2014-04-22 | Concert Pharmaceuticals, Inc. | Deuterated 2-amino-3-hydroxypropanoic acid derivatives |
BRPI0913457B8 (en) * | 2008-09-18 | 2021-08-31 | Auspex Pharmaceutical Inc | Compound and pharmaceutical composition |
BRPI0918760A2 (en) | 2008-09-19 | 2015-12-29 | Concert Pharmaceuticals Inc | morphinan compounds |
AU2013204067B2 (en) * | 2008-09-19 | 2014-02-27 | Concert Pharmaceuticals Inc. | Morphinan compounds |
AU2015258262B2 (en) * | 2008-09-19 | 2016-08-18 | Concert Pharmaceuticals Inc. | Morphinan compounds |
WO2010036773A1 (en) * | 2008-09-24 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives |
WO2010036796A1 (en) * | 2008-09-26 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Pyridineamine derivatives |
US20100113606A1 (en) * | 2008-11-05 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Aminopropanol modulators of beta-1 adrenergic receptor |
US20100113431A1 (en) * | 2008-11-05 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | N-methyl piperazine modulators of h1 receptor |
US8227451B2 (en) | 2008-11-12 | 2012-07-24 | Auspex Pharmaceuticals | Phenylacetic acid inhibitors of cyclooxygenase |
US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
US20100137215A1 (en) * | 2008-11-25 | 2010-06-03 | Concert Pharmaceuticals Inc. | Novel tetrahydro-1h-pyrido[4,3-b]indoles |
LT2716157T (en) | 2008-12-08 | 2016-09-12 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
SG10201707798SA (en) | 2008-12-08 | 2017-10-30 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
HU230067B1 (en) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Novel piperazine salt and preparation method thereof |
HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US8952016B2 (en) | 2009-02-27 | 2015-02-10 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US20110053961A1 (en) * | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US8563554B2 (en) | 2009-03-17 | 2013-10-22 | Concert Pharmaceuticals, Inc. | Deuterated pyrazinoisoquinoline compounds |
US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
CA2759026C (en) | 2009-04-20 | 2019-01-15 | Auspex Pharmaceuticals, Inc. | Piperidine inhibitors of janus kinase 3 |
US8461197B2 (en) | 2009-04-23 | 2013-06-11 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
US20100305173A1 (en) * | 2009-04-30 | 2010-12-02 | Concert Pharmaceuticals, Inc. | Hydroxyethylamino sulfonamide derivatives |
US20120058085A1 (en) * | 2009-05-15 | 2012-03-08 | Persichetti Rose A | Deuterium Modified Benzimidazoles |
US8410082B2 (en) | 2009-05-22 | 2013-04-02 | Concert Pharmaceuticals, Inc. | Fluorinated diaryl urea derivatives |
US20120244122A1 (en) * | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
US8586760B2 (en) | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
ME01883B (en) | 2009-06-18 | 2014-12-20 | Concert Pharmaceuticals Inc | Deuterated i soindoline- i, 3-dione derivatives as pde4 and tnf-alpha inhibitors |
US8501738B2 (en) | 2009-06-23 | 2013-08-06 | Concert Pharmaceuticals, Inc. | Substituted triazolo-pyridazine derivatives |
WO2011009075A2 (en) * | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
US8802850B2 (en) | 2009-07-27 | 2014-08-12 | Auspex Pharmaceuticals, Inc. | Cyclopropyl modulators of P2Y12 receptor |
US8637524B2 (en) | 2009-07-28 | 2014-01-28 | Auspex Pharmaceuticals, Inc | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 |
US8575348B2 (en) | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
US9512104B2 (en) | 2009-07-28 | 2016-12-06 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
EP2921486B1 (en) * | 2009-08-07 | 2017-09-27 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
US20110105603A1 (en) * | 2010-08-06 | 2011-05-05 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
US8530479B2 (en) * | 2009-08-10 | 2013-09-10 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides |
EP2464355A4 (en) | 2009-08-14 | 2013-01-02 | Concert Pharmaceuticals Inc | Substituted triazolophthalazine derivatives |
US8658236B2 (en) | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
CN101666757B (en) * | 2009-09-25 | 2011-03-16 | 广东省药品检验所 | Fast sieving method for dihydropyridine blood-pressure lowering compound mixed in Chinese medicinal herb blood-pressure lowering product |
KR20120110090A (en) * | 2009-09-28 | 2012-10-09 | 에프. 호프만-라 로슈 리미티드 | Novel macrocyclic inhibitors of hepatitis c virus replication |
US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
US9260424B2 (en) | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
KR20120092142A (en) * | 2009-10-28 | 2012-08-20 | 애나디스 파마슈티칼스, 인코포레이티드 | Deuterated 5,6-dihydro-1h-pyridin-2-one compounds |
EP2496563A4 (en) * | 2009-11-04 | 2013-04-03 | Sichuan Beilike Biotechnology Ltd Liability Company | Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof |
WO2011056764A1 (en) * | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
US8471034B2 (en) | 2009-11-18 | 2013-06-25 | Concert Pharmaceuticals, Inc. | Niacin prodrugs and deuterated versions thereof |
US20110152303A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Chemical Compounds |
CN103980338B (en) | 2010-01-15 | 2017-04-26 | 苏州润新生物科技有限公司 | Bufalin derivatives, pharmaceutical compositions and methods thereof |
EP2536696A1 (en) * | 2010-02-18 | 2012-12-26 | Concert Pharmaceuticals Inc. | Pyrimidine derivatives |
WO2011109464A1 (en) | 2010-03-02 | 2011-09-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
ES2530449T3 (en) | 2010-03-11 | 2015-03-02 | Gilead Connecticut Inc | Imidazopyridine Syk inhibitors |
US8575221B2 (en) | 2010-03-17 | 2013-11-05 | Concert Pharmaceuticals, Inc. | Derivatives of dimethylcurcumin |
AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (en) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
WO2012006070A1 (en) * | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
NZ606767A (en) | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
WO2012007839A2 (en) | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract |
EP2593474A2 (en) | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
WO2012009446A1 (en) | 2010-07-16 | 2012-01-19 | Concert Pharmaceuticals Inc. | Novel pyrimidinecarboxamide derivatives |
CN103119061A (en) | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | A method of treating attention deficit hyperactivity disorder |
CN102574890B (en) | 2010-08-23 | 2015-03-11 | 苏州润新生物科技有限公司 | Certain chemical entities, compositions, and methods |
WO2012027957A1 (en) | 2010-08-28 | 2012-03-08 | Suzhou Neupharma Co., Ltd. | Bufalin derivatives, pharmaceutical compositions and use thereof |
US9074233B2 (en) | 2010-09-01 | 2015-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
WO2012031072A1 (en) | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
WO2012051117A2 (en) | 2010-10-11 | 2012-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Substituted benzamides and their uses |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
EP3453714B1 (en) | 2011-02-02 | 2020-11-04 | Suzhou Neupharma Co., Ltd | Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof |
ES2804540T3 (en) | 2011-02-14 | 2021-02-08 | Concert Pharmaceuticals Inc | Deuterated analogs of 4-hydroxybutyric acid |
US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
US8889687B2 (en) | 2011-03-04 | 2014-11-18 | Concert Pharmaceuticals, Inc. | Deuterated pyrazinoisoquinoline compounds |
AU2012225611B2 (en) | 2011-03-08 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Substituted N-Aryl pyridinones |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2012151343A1 (en) * | 2011-05-04 | 2012-11-08 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
PL3235812T3 (en) * | 2011-05-18 | 2020-04-30 | Vertex Pharmaceuticals (Europe) Limited | Deuterated derivatives of ivacaftor |
HUE047354T2 (en) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Deuterated derivatives of ivacaftor |
US8691808B2 (en) | 2011-05-20 | 2014-04-08 | Influmedix, Inc. | Antiviral compounds and their methods of use |
EP2714624B1 (en) * | 2011-05-23 | 2017-12-27 | Sanofi | Process for the preparation of deuterated compounds containing n-alkyl groups |
US8778223B2 (en) | 2011-05-24 | 2014-07-15 | Lc Vision, Llc | Liquid crystals having cyclohexyl core structures and fluorinated tails |
MX361020B (en) | 2011-06-17 | 2018-11-26 | Pfizer Anti Infectives Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carbo xamide and salts thereof. |
MD4538C1 (en) | 2011-06-20 | 2018-07-31 | H. Lundbeck A/S | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia |
ES2725790T3 (en) | 2011-08-26 | 2019-09-27 | Neupharma Inc | Some chemical entities, compositions, and methods |
EP2753174A4 (en) | 2011-09-01 | 2015-05-20 | Xiangping Qian | Certain chemical entities, compositions, and methods |
AU2012308238B2 (en) | 2011-09-14 | 2017-05-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
SG11201402401TA (en) | 2011-11-18 | 2014-06-27 | Codexis Inc | Biocatalysts for the preparation of hydroxy substituted carbamates |
IL298436B1 (en) | 2012-01-23 | 2024-03-01 | Sage Therapeutics Inc | Pharmaceutical compositions comprising allopregnanolone |
WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2013132263A1 (en) * | 2012-03-09 | 2013-09-12 | Axelar Ab | Picropodophyllin derivatives for use in therapy |
SG11201406311UA (en) | 2012-04-05 | 2014-11-27 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
KR20150013475A (en) | 2012-04-12 | 2015-02-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Substituted benzamides and their uses |
IN2014DN08443A (en) | 2012-04-13 | 2015-05-08 | Concert Pharmaceuticals Inc | |
WO2013159026A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
CN109354598A (en) | 2012-04-29 | 2019-02-19 | 润新生物公司 | Chemical entity, pharmaceutical composition and cancer treatment method |
US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
CN102757417B (en) | 2012-06-18 | 2014-09-24 | 中国科学院广州生物医药与健康研究院 | Deuterated benzopyran compound and application thereof |
WO2014008417A1 (en) | 2012-07-04 | 2014-01-09 | Concert Pharmaceuticals, Inc. | Deuterated vercirnon |
EP2885267B1 (en) | 2012-07-12 | 2018-09-05 | Concert Pharmaceuticals, Inc. | Deuterated idebenone |
MX2015001246A (en) | 2012-07-30 | 2015-04-10 | Concert Pharmaceuticals Inc | Deuterated ibrutinib. |
GB201214169D0 (en) * | 2012-08-08 | 2012-09-19 | Biostatus Ltd | New compounds and uses thereof |
EA031716B1 (en) | 2012-08-17 | 2019-02-28 | Консерт Фармасьютикалс, Инк. | Deuterated baricitinib |
CN104736202B (en) | 2012-08-22 | 2021-09-07 | 康奈尔大学 | Methods for inhibiting fascin |
US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
NZ705372A (en) | 2012-09-18 | 2018-07-27 | Auspex Pharmaceuticals Inc | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
CN104812389B (en) | 2012-09-24 | 2020-07-17 | 润新生物公司 | Certain chemical entities, compositions, and methods |
US9643950B2 (en) | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
JP6146990B2 (en) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated CFTR enhancer |
CN103833630B (en) * | 2012-11-21 | 2018-11-13 | 顶点制药(欧洲)有限公司 | Deuterate CFTR synergist |
US20150299166A1 (en) * | 2012-12-20 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Deuterated alk inhibitors |
AU2014205472B2 (en) | 2013-01-09 | 2018-05-10 | Concert Pharmaceuticals Inc. | Deuterated momelotinib |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
JP2016506957A (en) * | 2013-01-31 | 2016-03-07 | オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. | VMAT2 benzoquinolone inhibitor |
GB201302368D0 (en) * | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2014152843A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
BR112015023392A2 (en) | 2013-03-15 | 2017-07-18 | Deuteria Agrochemicals Llc | composition and method of insect behavior modulation |
US9713330B1 (en) | 2013-03-15 | 2017-07-25 | Deuteria Agrochemicals, Llc | Deuterium-enriched aldehydes |
CA2906396A1 (en) | 2013-03-15 | 2014-09-25 | Concert Pharmaceuticals Inc. | Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase |
CN104109149B (en) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | Deuterated diaminopyrimidine compounds and the pharmaceutical composition comprising the compound |
EP3027171B1 (en) | 2013-07-30 | 2020-03-25 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
HUE043465T2 (en) | 2013-08-23 | 2019-08-28 | Neupharma Inc | Certain chemical entities, compositions, and methods |
WO2015031741A1 (en) | 2013-08-30 | 2015-03-05 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor |
EA201791466A1 (en) | 2013-12-03 | 2017-11-30 | Оспекс Фармасьютикалз, Инк. | METHODS OF OBTAINING COMPOUNDS BENZOHINOLINE |
EP3666271A1 (en) | 2013-12-03 | 2020-06-17 | Intra-Cellular Therapies, Inc. | Miscrospheres comprising a plga matrix for medical use |
KR20180002888A (en) | 2013-12-04 | 2018-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Methods for treating cancers |
US9732031B2 (en) | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
UY35898A (en) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
EP3089746A4 (en) | 2013-12-30 | 2017-08-30 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
JP6526060B2 (en) * | 2014-02-10 | 2019-06-05 | コンサート ファーマシューティカルズ インコーポレイテッド | Substituted triazolobenzodiazepines |
JP6691869B2 (en) | 2014-02-20 | 2020-05-13 | コーネル ユニヴァーシティー | Compounds and methods for inhibiting fascin |
EP3125893B1 (en) * | 2014-04-04 | 2023-09-20 | Intra-Cellular Therapies, Inc. | Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors |
US9884872B2 (en) * | 2014-06-20 | 2018-02-06 | Intra-Cellular Therapies, Inc. | Organic compounds |
NZ726365A (en) | 2014-07-14 | 2018-06-29 | Gilead Sciences Inc | Combinations for treating cancers |
KR102457848B1 (en) | 2014-09-17 | 2022-10-25 | 셀젠 카르 엘엘씨 | Mk2 inhibitors and uses thereof |
US10160778B2 (en) | 2014-10-27 | 2018-12-25 | Concert Pharmaceuticals, Inc. | Pyrimidine phosphonic acid esters |
US9950995B2 (en) * | 2014-10-29 | 2018-04-24 | Center Laboratories, Inc. | Crystal forms of verapamil hydrochloride |
JP2017533923A (en) | 2014-11-06 | 2017-11-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | Bile acid analogs as FXR / TGR5 agonists and methods of use thereof |
US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
US20160214918A1 (en) * | 2015-01-22 | 2016-07-28 | Kaohsiung Medical University | Composition for treating metabolic syndrome and a preparation method thereof |
CN105985396A (en) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | Deuterated chenodeoxycholic acid derivative and pharmaceutical composition containing same |
AU2016220219B2 (en) | 2015-02-17 | 2020-05-14 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
EA201791977A1 (en) | 2015-03-06 | 2018-01-31 | Оспекс Фармасьютикалз, Инк. | METHODS OF TREATMENT OF PATHOLOGICAL INDUSTRIAL MOVEMENTS |
WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
SG10201910670RA (en) | 2015-03-31 | 2020-01-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
EP3280420B1 (en) * | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
CN106279039B (en) * | 2015-06-02 | 2019-01-11 | 青岛海洋生物医药研究院股份有限公司 | Deuterated dehydrophenylahistin class compound and preparation method thereof and preparing the application in anti-tumor drug |
US10981893B2 (en) | 2015-07-01 | 2021-04-20 | Attune Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
MA42954A (en) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | DEUTERATED CFTR POTENTIALIZERS |
US10414735B2 (en) | 2015-11-09 | 2019-09-17 | Forge Therapeutics, Inc. | Substituted hydroxypyrimidinones for treating bacterial infections |
WO2017087795A1 (en) | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
DE212016000029U1 (en) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct agonist conjugates |
CN106892924B (en) * | 2015-12-17 | 2021-01-08 | 四川科伦博泰生物医药股份有限公司 | Short-acting benzodiazepine derivatives, method for the production thereof and use thereof |
EP3416629A4 (en) | 2016-02-16 | 2019-08-07 | CoNCERT Pharmaceuticals, Inc. | Deuterated gft-505 |
US10364267B2 (en) * | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
WO2017143874A1 (en) * | 2016-02-25 | 2017-08-31 | 深圳市塔吉瑞生物医药有限公司 | Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof |
MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
EP3888656A1 (en) | 2016-03-25 | 2021-10-06 | Intra-Cellular Therapies, Inc. | Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
AU2017312561B2 (en) | 2016-08-15 | 2022-06-30 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US10912769B2 (en) * | 2016-09-29 | 2021-02-09 | Jiangsu Jibeier Pharmaceutical Co. Ltd. | 1-[(pyridin-3-yl-sulfonyl)-1H-pyrrol-3-yl] methanamine derivative and pharmaceutical composition and use thereof |
JP7013454B2 (en) | 2016-10-12 | 2022-02-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | Amorphous solid dispersion |
JP2017105824A (en) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated cftr enhancement material |
WO2018170179A1 (en) | 2017-03-15 | 2018-09-20 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
EP3596085A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | Deuterated analogs of mk2 inhibitors and uses thereof |
US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
EP3596084A4 (en) | 2017-03-16 | 2020-12-23 | Celgene CAR LLC | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof |
MX2021013640A (en) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Novel compositions and methods. |
EP3621962A4 (en) | 2017-05-10 | 2020-12-09 | Forge Therapeutics, Inc. | Antibacterial compounds |
WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
CN107226769A (en) * | 2017-06-19 | 2017-10-03 | 郑州泰基鸿诺医药股份有限公司 | A kind of deuterated methoxy containing difluoro(Sulphur)The synthetic method of the aromatic compounds of base functional group |
CN109422731A (en) * | 2017-08-24 | 2019-03-05 | 正大天晴药业集团股份有限公司 | Deuterated quinoline |
JP6986624B2 (en) | 2017-08-25 | 2021-12-22 | ギリアード サイエンシーズ, インコーポレイテッド | Polymorph of Syk inhibitor |
US11267810B2 (en) | 2017-08-30 | 2022-03-08 | Shenzhen Targetrx, Inc. | Aminopyrimidine compound and composition comprising same and use thereof |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugates and methods of use thereof for selective delivery of immune-modulatory agents |
CN109438362B (en) * | 2017-11-14 | 2020-07-21 | 深圳市塔吉瑞生物医药有限公司 | Substituted benzimidazole compound and composition containing same |
WO2019104179A1 (en) | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
SG11202004264VA (en) | 2017-12-01 | 2020-06-29 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
KR20200096596A (en) * | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Deuterated 21-[4-cyano-pyrazole-1-yl]-19-nor-pregan-3 for the treatment of CNS disorders. Alpha-ol-20-one derivative |
TWI780281B (en) * | 2017-12-14 | 2022-10-11 | 丹麥商Nmd藥品公司 | Compounds for the treatment of neuromuscular disorders |
AU2018385693A1 (en) | 2017-12-15 | 2020-06-18 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
JP7150356B2 (en) * | 2017-12-22 | 2022-10-11 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | Substituted pyrazolo[1,5-a]pyrimidine compounds and pharmaceutical compositions and uses thereof |
UY38057A (en) | 2018-01-19 | 2019-08-30 | Cytokinetics Inc | CARDIAC SARCOMER INHIBITORS |
WO2019144885A1 (en) | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound |
WO2019152883A1 (en) | 2018-02-02 | 2019-08-08 | Padforward Llc | Inhibitors of protein arginine deiminases |
JP2021512893A (en) | 2018-02-08 | 2021-05-20 | ニューファーマ,インク. | Specific chemicals, compositions, and methods |
MX2020009563A (en) * | 2018-03-21 | 2020-10-05 | Izumi Tech Llc | Deuterated analogs of elacridar. |
EP3774798A1 (en) | 2018-04-02 | 2021-02-17 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
MX2020012679A (en) | 2018-05-25 | 2021-02-09 | Silverback Therapeutics Inc | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof. |
EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
JP7438148B2 (en) | 2018-06-26 | 2024-02-26 | サイトキネティックス, インコーポレイテッド | cardiac sarcomere inhibitor |
BR112020026748A2 (en) | 2018-06-29 | 2021-03-30 | Kinnate Biopharma Inc. | CYCLINE DEPENDENT KINASE INHIBITORS |
JP6654223B2 (en) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド | Deuterated CFTR enhancer |
CN109020875B (en) * | 2018-08-27 | 2020-05-22 | 北京市药品检验所 | Dihydropyridine compound dehydroaromatization method and application thereof in drug detection |
BR112021003655A2 (en) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | new methods |
EA202190657A1 (en) | 2018-08-31 | 2021-07-22 | Сайтокинетикс, Инк. | HEART SARCOMER INHIBITORS |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
JP2021536488A (en) * | 2018-09-05 | 2021-12-27 | ルパン インコーポレイテッド | Deuterated secnidazole for use in the treatment of bacterial vaginosis and its methods and uses |
EP3849971A2 (en) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
CN113166077A (en) | 2018-09-20 | 2021-07-23 | 福至治疗公司 | Antibacterial compounds |
CN113194977A (en) | 2018-10-16 | 2021-07-30 | 格罗制药公司 | Nicotinamide acetylcholine receptor peptide antagonist conotoxin compositions and related methods |
WO2020097258A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
CN113272291A (en) | 2018-11-06 | 2021-08-17 | 艾知怀斯治疗学公司 | Pyridazinone compound and use thereof |
EA202191082A1 (en) | 2018-11-06 | 2021-09-10 | Эджвайз Терапьютикс, Инк. | COMPOUNDS OF PYRIDAZINONES AND THEIR APPLICATIONS |
CN113056457A (en) | 2018-12-03 | 2021-06-29 | H.隆德贝克有限公司 | 4- ((1R,3S) -6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl) -1,2, 2-trimethylpiperazine and 4- ((1R,3S) -6-chloro-3- (phenyl-d)5) -2, 3-dihydro-1H-inden-1-yl) -2, 2-dimethyl-1- (methyl-d3) Prodrugs of piperazine |
AR117228A1 (en) * | 2018-12-06 | 2021-07-21 | Arisan Therapeutics | DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION |
MA54289A (en) * | 2018-12-06 | 2021-10-06 | Intrabio Ltd | DEUTERATED ANALOGS OF ACETYL-LEUCINE |
JP7061236B2 (en) | 2019-01-22 | 2022-04-27 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC Modulator and Its Use |
CA3130693A1 (en) | 2019-02-19 | 2020-08-27 | Ultima Genomics, Inc. | Linkers and methods for optical detection and sequencing |
KR20210131372A (en) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Solid Form of Condensed Pyrazine as Syk Inhibitor |
CA3131104A1 (en) | 2019-03-06 | 2020-09-10 | Silverback Therapeutics, Inc. | Cyclic amino-pyrazinecarboxamide compounds and uses thereof |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
JP2022530322A (en) | 2019-04-18 | 2022-06-29 | アズーラ オフサルミックス エルティーディー. | Compounds and methods for treating eye disorders |
CN114007625A (en) | 2019-04-18 | 2022-02-01 | 阿祖拉眼科有限公司 | Compounds and methods for treating ocular diseases |
TW202106684A (en) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Inhibitors of raf kinases |
WO2020226628A1 (en) | 2019-05-07 | 2020-11-12 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs for treating opioid dependence |
WO2020247546A1 (en) | 2019-06-03 | 2020-12-10 | Biointervene, Inc. | Adenosine analogs for the treatment of disease |
WO2020247540A1 (en) | 2019-06-03 | 2020-12-10 | Biointervene, Inc. | Adenosine analogs for the treatment of disease |
EP3996714A4 (en) | 2019-07-08 | 2023-07-19 | Belite Bio, LLC | Formulations of rbp4 inhibitors and methods of use |
US20210139477A1 (en) | 2019-07-16 | 2021-05-13 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
WO2021055376A1 (en) | 2019-09-16 | 2021-03-25 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
AU2020358726A1 (en) | 2019-10-01 | 2022-04-07 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
BR112022006546A2 (en) | 2019-10-07 | 2022-08-30 | Kallyope Inc | GPR119 AGONISTS |
WO2021072330A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases |
WO2021072203A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof |
MX2022004937A (en) | 2019-10-24 | 2022-07-27 | Kinnate Biopharma Inc | Inhibitors of raf kinases. |
WO2021102332A1 (en) | 2019-11-22 | 2021-05-27 | Silverback Therapeutics, Inc. | Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof |
EP4069699A1 (en) | 2019-12-05 | 2022-10-12 | Verge Analytics, Inc. | Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases |
AU2021207804A1 (en) | 2020-01-13 | 2022-09-01 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
CN115515934A (en) | 2020-02-07 | 2022-12-23 | 赛特凯恩蒂克公司 | NAMPT modulators |
US11807851B1 (en) | 2020-02-18 | 2023-11-07 | Ultima Genomics, Inc. | Modified polynucleotides and uses thereof |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
EP4118087A1 (en) | 2020-03-09 | 2023-01-18 | Verge Analytics, Inc. | Substituted furo[3,2-d]pyrimidines and uses thereof |
WO2021195260A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
KR20230019431A (en) | 2020-05-04 | 2023-02-08 | 볼라스트라 쎄라퓨틱스, 인코포레이티드 | Iminosulfanone inhibitor of ENPP1 |
CA3181351A1 (en) | 2020-05-06 | 2021-11-11 | Antonio Romero | Nampt modulators |
JP2023526248A (en) | 2020-05-13 | 2023-06-21 | エッジワイズ セラピューティクス, インコーポレイテッド | Pyridazinone compounds for the treatment of neuromuscular diseases |
EP4149465A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
EP4149621A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
EP4149467A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
WO2021231630A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
WO2021231726A1 (en) | 2020-05-14 | 2021-11-18 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
MX2022014505A (en) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Ampk activators. |
KR20230035031A (en) | 2020-06-05 | 2023-03-10 | 킨네이트 바이오파마 인크. | Inhibitors of fibroblast growth factor receptor kinase |
TW202214640A (en) | 2020-06-16 | 2022-04-16 | 美商佛拉斯托醫療公司 | Heterocyclic inhibitors of enpp1 |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
EP4185590A2 (en) | 2020-07-21 | 2023-05-31 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
EP4196219A1 (en) | 2020-08-17 | 2023-06-21 | Biointervene, Inc. | A3 adenosine receptor agonists for use in medicine |
CN111995574A (en) * | 2020-08-28 | 2020-11-27 | 西安明喆药品生产有限公司 | Deuterated hydroxychloroquine derivative and pharmaceutical composition containing same |
US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
CA3176635A1 (en) | 2020-11-06 | 2022-05-12 | Cytokinetics, Inc. | Bicyclic 1,4-diazepanones and therapeutic uses thereof |
CA3198344A1 (en) | 2020-11-20 | 2022-05-27 | Patrick T. GUNNING | Methods and composition for kras modifications |
GB2617477A (en) | 2020-11-20 | 2023-10-11 | 2692372 Ontario Inc | Benzenesulfonamide derivatives and uses thereof |
JP2024501233A (en) | 2020-12-21 | 2024-01-11 | サイトキネティックス, インコーポレイテッド | Pyrazole derivatives useful as NAMPT modulators |
WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
TW202245753A (en) | 2021-02-24 | 2022-12-01 | 香港商英科智能有限公司 | Analogs for the treatment of disease |
US11919909B2 (en) | 2021-03-04 | 2024-03-05 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
EP4320103A1 (en) | 2021-04-09 | 2024-02-14 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
CN117561057A (en) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | Treatment of cancer with RAF inhibitors |
KR20240019091A (en) * | 2021-04-23 | 2024-02-14 | 길가메쉬 파마슈티컬스, 인코포레이티드 | Novel ergoline and treatment methods for mood disorders |
AR126010A1 (en) | 2021-06-01 | 2023-08-30 | Verge Analytics Inc | FUSED BICYCLIC HETEROCYCLIC COMPOUNDS AND USES THEREOF |
WO2022256298A1 (en) | 2021-06-01 | 2022-12-08 | Verge Analytics, Inc. | 7-(3-phenyl-1 h-pyrazol-1-yl)-5-morpholino-imidazo[1,2-a]pyrimidine derivatives and similar compounds as pikfyve kinase inhibitors for the treatment of e.g. amyotrophic lateral sclerosis (als) |
WO2022256297A1 (en) | 2021-06-01 | 2022-12-08 | Verge Analytics, Inc. | 2-(3-phenyl-1h-pyrazol-1-yl)-4-morpholino-5h-pyrrolo[3,2-d]pyrimidine derivatives and similar compounds as pikfyve kinase inhibitors for the treatment of e.g. amyotrophic lateral sclerosis (als) |
TW202313619A (en) | 2021-06-01 | 2023-04-01 | 美商邊際分析公司 | Fused bicyclic heterocyclic compounds and uses thereof |
WO2022261068A1 (en) | 2021-06-08 | 2022-12-15 | Verge Analytics, Inc. | Methods and treatment of viral infection with substituted furo-pyrimidines |
WO2022263829A1 (en) | 2021-06-16 | 2022-12-22 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
AU2022298746A1 (en) | 2021-06-24 | 2023-11-30 | Insilico Medicine Ip Limited | Beta-lactam derivatives for the treatment of diseases |
CA3224467A1 (en) | 2021-07-09 | 2023-01-12 | Dice Alpha, Inc. | Phenyl acetamide based il-17a modulators and uses thereof |
AU2022310682A1 (en) | 2021-07-12 | 2024-01-25 | Cytokinetics, Inc. | Cd38 modulators and methods of use thereof |
CA3230123A1 (en) | 2021-08-26 | 2023-03-02 | Derek A. Cogan | Spiro indoline inhibitors of kif18a |
WO2023070114A2 (en) | 2021-10-22 | 2023-04-27 | Terremoto Biosciences, Inc. | Reversible lysine covalent modifiers of egfr and uses thereof |
WO2023076866A1 (en) | 2021-10-25 | 2023-05-04 | Volastra Therapeutics, Inc. | Tricyclic sulfoximine inhibitors of enpp1 |
WO2023081312A1 (en) | 2021-11-04 | 2023-05-11 | Vir Biotechnology, Inc. | Small molecule inducers of autophagy |
TW202334142A (en) | 2021-11-12 | 2023-09-01 | 香港商英矽智能科技知識產權有限公司 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
WO2023086638A1 (en) | 2021-11-15 | 2023-05-19 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
WO2023091606A1 (en) | 2021-11-17 | 2023-05-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
WO2023114733A1 (en) | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
WO2023114428A1 (en) | 2021-12-16 | 2023-06-22 | Vir Biotechnology, Inc. | Heterocycle derivatives for the treatment of disease |
TW202333709A (en) | 2021-12-16 | 2023-09-01 | 美商奇奈特生物製藥公司 | Inhibitors of met kinase |
WO2023150681A1 (en) | 2022-02-03 | 2023-08-10 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
WO2023154766A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
WO2023164057A1 (en) | 2022-02-25 | 2023-08-31 | Dice Alpha, Inc. | Di-cyclopropyl based il-17a modulators and uses thereof |
WO2023168291A1 (en) | 2022-03-02 | 2023-09-07 | Terremoto Biosciences, Inc. | Covalent modifiers of akt1 and uses thereof |
TW202342018A (en) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Inhibitors of mek kinase |
TW202400787A (en) | 2022-03-16 | 2024-01-01 | 美商安彼瑞可股份有限公司 | Galnac compositions for improving sirna bioavailability |
WO2023198873A1 (en) * | 2022-04-14 | 2023-10-19 | Immunic Ag | Deuterated rorgamma/rorgammat inverse agonists |
US20230382889A1 (en) | 2022-04-28 | 2023-11-30 | Volastra Therapeutics, Inc. | Compounds for inhibiting kif18a |
WO2023215367A1 (en) | 2022-05-04 | 2023-11-09 | Cytokinetics, Inc. | Bicyclic piperazinones and therapeutic uses thereof |
WO2023220741A1 (en) | 2022-05-13 | 2023-11-16 | Dice Molecules Sv, Inc. | Alpha 4 beta 7 integrin modulators and uses thereof |
WO2023225001A1 (en) | 2022-05-16 | 2023-11-23 | Vir Biotechnology, Inc. | Naphthyridine based enpp1 modulators and uses thereof |
US11939335B2 (en) | 2022-05-17 | 2024-03-26 | 858 Therapeutics, Inc. | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG |
WO2023225664A1 (en) | 2022-05-19 | 2023-11-23 | Dice Alpha, Inc. | Lactam substituted imidazopyridazine il-17a modulators and uses thereof |
WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
WO2023235880A1 (en) | 2022-06-02 | 2023-12-07 | Aeovian Pharmaceuticals, Inc. | Cd38 modulators and uses thereof |
WO2023245137A1 (en) | 2022-06-16 | 2023-12-21 | Cytokinetics, Incorporated | Slow skeletal troponin activators |
WO2024020419A1 (en) | 2022-07-18 | 2024-01-25 | Iambic Therapeutics, Inc. | Aza-quinazoline compounds and methods of use |
WO2024020380A1 (en) | 2022-07-18 | 2024-01-25 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
WO2024020517A1 (en) | 2022-07-22 | 2024-01-25 | 858 Therapeutics, Inc. | 3-(6-pyridin-3-yl)-2-[4-(4-methyl-4h-1,2,4-triazol-3-yl)piperidin-1-yl]benzonitrile derivatives and similar compounds as qpctl and qpct inhibitors for the treatment of cancer |
WO2024030825A1 (en) | 2022-08-01 | 2024-02-08 | Neupharma, Inc | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
WO2024040190A1 (en) | 2022-08-18 | 2024-02-22 | Cytokinetics, Incorporated | Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors |
WO2024064701A2 (en) | 2022-09-20 | 2024-03-28 | Biointervene, Inc. | Adenosine analogs for the treatment of disease |
WO2024073426A1 (en) | 2022-09-26 | 2024-04-04 | Edgewise Therapeutics, Inc. | 1,4-dihydroquinazolinone compounds and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL302544A (en) * | 1963-12-24 | |||
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
FR2449448B1 (en) * | 1979-02-20 | 1983-05-27 | Inst Nat Radio Elements | PHARMACEUTICAL COMPOSITION COMPRISING A PHENYLHYDANTOIN DERIVATIVE, DERIVATIVES IMPLEMENTED AND THEIR PREPARATION |
CA1160226A (en) * | 1980-07-15 | 1984-01-10 | Gordon H. Phillipps | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor |
US4675338A (en) * | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
US5169773A (en) * | 1984-10-04 | 1992-12-08 | Sandoz Ltd. | Monoclonal antibodies to cyclosporins |
US5149820A (en) * | 1987-03-11 | 1992-09-22 | Norsk Hydro A.S. | Deuterated compounds |
GB8705780D0 (en) * | 1987-03-11 | 1987-04-15 | Norsk Hydro As | Anticancer compounds |
ES2059558T3 (en) * | 1987-06-17 | 1994-11-16 | Sandoz Ag | CYCLOSPORINS AND THEIR USE AS PHARMACEUTICAL PRODUCTS. |
EP0373260B1 (en) * | 1987-06-22 | 1994-03-09 | Merck & Co. Inc. | Cyclosporin derivatives with modified "8-amino acid" |
US5227467A (en) * | 1987-08-03 | 1993-07-13 | Merck & Co., Inc. | Immunosuppressive fluorinated cyclosporin analogs |
US5149846A (en) * | 1987-09-14 | 1992-09-22 | Hoffmann-La Roche Inc. | Deuterated analogs of 1,25-dihydroxycholecalciferol |
US4898855A (en) * | 1987-09-14 | 1990-02-06 | Hoffman-La Roche Inc. | Deuterated analogs of 1,25-dihydroxycholecalciferol |
US5247123A (en) * | 1987-09-14 | 1993-09-21 | Hoffmann-La Roche Inc. | Deuterated analogs of 1,25-dihydroxycholecalciferol |
US5012052A (en) * | 1988-03-22 | 1991-04-30 | Indiana University Foundation | Isotope-ratio-monitoring gas chromatography-mass spectrometry apparatus and method |
GB8810173D0 (en) * | 1988-04-29 | 1988-06-02 | Norsk Hydro As | Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer |
GB8921285D0 (en) * | 1989-09-20 | 1989-11-08 | Vg Instr Group | Isotopic composition analyzer |
US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
US5164308A (en) * | 1990-05-21 | 1992-11-17 | Martek Corporation | Preparation of labelled triglyceride oils by cultivation of microorganisms |
FR2673291A1 (en) * | 1991-02-27 | 1992-08-28 | Inbiomed International | Method for authenticating the origin of a product consisting of a mixture of organic compounds by means of isotopic labelling (tracing) |
US5432058A (en) * | 1992-09-30 | 1995-07-11 | Lange, Iii; Louis G. | Method for measuring human cholesterol absorption using metabolically stable isotopes |
WO1994012475A1 (en) * | 1992-11-27 | 1994-06-09 | Yason S.R.L. | Indole derivative having prolonged immunostimulating activity and pharmaceutical compositions therefrom |
US5424539A (en) * | 1992-12-18 | 1995-06-13 | Finnegan Mat Gmbh | Process for the analysis of gaseous components by mass spectrometry |
-
1995
- 1995-03-27 KR KR10-2004-7010591A patent/KR20040068613A/en not_active Application Discontinuation
- 1995-03-27 ES ES95912109T patent/ES2293638T3/en not_active Expired - Lifetime
- 1995-03-27 BR BR9507200A patent/BR9507200A/en not_active Application Discontinuation
- 1995-03-27 DE DE69535592T patent/DE69535592T2/en not_active Expired - Lifetime
- 1995-03-27 AU AU19441/95A patent/AU707748B2/en not_active Ceased
- 1995-03-27 CN CN95193186A patent/CN1087725C/en not_active Expired - Fee Related
- 1995-03-27 KR KR1019960705390A patent/KR100477070B1/en not_active IP Right Cessation
- 1995-03-27 CA CA002186371A patent/CA2186371A1/en not_active Abandoned
- 1995-03-27 WO PCT/CA1995/000154 patent/WO1995026325A2/en active IP Right Grant
- 1995-03-27 AT AT95912109T patent/ATE372966T1/en not_active IP Right Cessation
- 1995-03-27 JP JP52488595A patent/JP3696884B2/en not_active Expired - Fee Related
- 1995-03-27 EP EP95912109A patent/EP0751926B1/en not_active Expired - Lifetime
-
1996
- 1996-10-04 US US08/725,992 patent/US5846514A/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995026325B1 (en) | Enhancement of the efficacy of drugs by deuteration | |
AU707748B2 (en) | Enhancement of the efficacy of drugs by deuteration | |
Lee et al. | Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism | |
US20040253180A1 (en) | Method of making and using isotope-substituted anti-bacterial agents | |
CA1253856A (en) | Brain-specific drug delivery | |
SI22888A (en) | Polymorphs of donepezil hydrochloride and process for production | |
NZ517520A (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
Shohin et al. | In vitro dissolution kinetics of amlodipine tablets marketed in Russia under biowaiver conditions | |
Hussain et al. | Buccal and oral bioavailability of naloxone and naltrexone in rats | |
Bondesson et al. | Clinical pharmacokinetics and oral bioavailability of ketobemidone | |
CN102342942B (en) | A kind of New oral solid medicinal compositions and preparation method thereof | |
Stenbaek et al. | Pharmacokinetics of methyldopa in healthy man | |
JPS56133217A (en) | Lasting nicardipine pharmaceutical composition | |
CA2147762A1 (en) | Circulatory disorder improving agent | |
AU656574B2 (en) | Complexes of polyadenylic acid with polyuridylic acid | |
IMAMURA et al. | Effect of simultaneous administration of drugs on absorption and excretion. XV. Effect of probenecid on plasma protein binding of sulfadimethoxine in rabbits: the role of N4-acetylsulfadimethoxine, the major metabolite of sulfadimethoxine | |
Linden et al. | N, N-Diethyl-2, 6, 6-trimethyl-4-(3-nitrophenyl)-5-oxo-1, 4, 5, 6, 7, 8-hexahydroquinoline-3-carboxamide | |
Bohlooli et al. | Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats | |
JPH0326167B2 (en) | ||
Linden et al. | Methyl 4-(2-chloro-5-nitrophenyl)-2, 7, 7-trimethyl-5-oxo-1, 4, 5, 6, 7, 8-hexahydroquinoline-3-carboxylate | |
Osumi et al. | Antihypertensive effects of NKY-722, a water-soluble, dihydropyridine-type Ca2+ antagonist | |
Yamada et al. | In vivo receptor occupancy and plasma concentration of pranidipine, a potent and long-acting dihydropyridine calcium antagonist | |
Yamada et al. | Correlation Between the Plasma Concentration of Mepirodipine and Its Occupancy of Ca 2+ Antagonist Receptors in Rats | |
Jawahar et al. | Polymorphism: A Dissolution Rate Enhancement Technique of Nitrendipine | |
Lee et al. | Pharmacokinetics of a non‐narcotic analgesic, DA‐5018, in rats |